Phase II Trial of Erlotinib Plus Bevacizumab for Patients with Advanced Non-Small-Cell Lung Cancer Who are harboring an EGFR mutation.
Phase of Trial: Phase II
Latest Information Update: 07 Jul 2011
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Jul 2011 New trial record